GEN Exclusives

More »

Emerging Technologies

More »
Aug 1, 2009 (Vol. 29, No. 14)

GEN Update on Promising Emerging Biotechnologies

  • GEN is pleased to introduce a new column that will appear throughout the editorial year.It will highlight emerging university or academic technologies that have future applications in the commercial biotech and pharma arenas. GEN first discussed each of these novel methodologies in one of our weekly podcasts and we invite you to go to to learn more about the discovery and potential of each of these technologies.

  • Click Image To Enlarge +
    The noninvasive delivery of stem cells to the brain in an animal model offers hope for a new way of treating neurological diseases in humans in the future.
    (Yang MingQi -


    William Frey, Ph.D., codirector, Alzheimer’s Research Center, Regions Hospital, St. Paul, MN, and professor, oral biology and pharmaceutics, University of Minnesota.
    GEN Podcast, July 16, 2009.

    For decades the blood-brain barrier has served as the major obstacle to the use of many therapeutic agents for central nervous system disorders. However, a noninvasive, intranasal method of bypassing the blood-brain barrier to deliver drugs to the brain and spinal cord was revealed by Dr. Frey in 1992.

    Now Dr. Frey and collaborators in Germany report that stem cells can be noninvasively delivered to the brain using the intranasal method. They accomplished this goal in an animal model and noted that they bypassed the blood-brain barrier.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »